Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Acorda Therapeutics Inc
ACORQ
Healthcare
Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa...
/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ACORQ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 15, 2024 5:17pm
ACOR...Don't let the door hit ya in the butt when ur leaving
Acorda Therapeutics Announces Delisting from Nasdaq 2024-04-15 14:03 ET - News Release Company Website: https://www.acorda.com/ PEARL RIVER, N.Y. -- (Business
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Apr 02, 2024 11:25am
ACOR.....1st scalp of the day.....70 cent profit /sh
Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement 2024-04-01 15:35 ET - News Release Acorda Files for
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 05, 2022 7:06am
New Press Release - Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture. Acorda may elect to make interest payments under the Indenture in cash or shares of the...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 21, 2022 3:41pm
ACOR..... Consider yourselves.... "Had"
Thats right.....u've all been had ....again !!!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Nov 21, 2022 3:36pm
RE:ACOR ..... Don't kid yourself for a minute.....
LMFAO .......it took a while but this is just about ready to drop like rock !!!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 11, 2022 9:52am
New Press Release - Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company’s stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders. “We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 08, 2022 10:51am
ACOR ..... Wasn't the open exciting ; )
Had all the "Bagholders" & "Chasers" holding their breath....and low & behold this is about to go sub $0.60...wait for it....jmho FYI ..... sh price has broken the ST RBL
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 07, 2022 11:58am
ACOR ..... Don't kid yourself for a minute.....
This isn't "The Rug Pull".... wait for it bagholders ; ) JMHO
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 04, 2022 2:17pm
ACOR .... I guess they need more time....
So they do "The Rug Pull"
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 04, 2022 12:28pm
ACOR .. I can't believe this...Mtg Adjourned again !!! WTF
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders 2022-11-04 06:25 ET - News Release
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 04, 2022 9:26am
New Press Release - Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Scheduled to Reconvene November 11, 2022 at 9:00 a.m. Eastern Time at the Company’s Headquarters to Vote on Proposal Two Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 01, 2022 7:43pm
ACOR ...... I regret to inform you After Hours trading
has not been good to ACOR............72 facking cents !!! Theres always tomorrow ; ) Can it get worse? Hell ya !
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 01, 2022 4:03pm
New Press Release - Acorda Therapeutics Reports Third Quarter 2022 Financial Results
INBRIJA® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award and royalty/supply relief in AMPYRA arbitration case Special Meeting of Stockholders...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 01, 2022 3:42pm
ACOR .... Now who do u believe?
Me ..... or the man behind the curtain? You've all been had...... again Lies ...lies......lies.....those sweet little lies !!!! Is that a song?
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Nov 01, 2022 1:40pm
ACOR ....going to Hell in a hand-basket
Don't let the door hit you in the a$$ when ur leavin !!!!
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >